| Catalog Number |
1000080 |
| Medical Device Problem Code |
Adverse Event Without Identified Device or Use Problem (2993)
|
| Health Effect - Clinical Code |
Hemorrhage/Blood Loss/Bleeding (1888)
|
| Date of Event |
03/20/2026
|
|
Type of Reportable Event
|
Death
|
|
Additional Manufacturer Narrative
|
|
This report is being submitted pursuant to the provisions of 21 cfr, part 803.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by abiomed inc or its employees that the report constitutes an admission that the product, abiomed inc, or its employees, caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.
|
| |
|
Event or Problem Description
|
|
An impella cp device was inserted into the right femoral artery in a 68-year-old male patient with a past medical history of coronary artery bypass graft (cabg) and coronary artery disease (cad), presenting in acute myocardial infarction (ami) and cardiogenic shock (cgs), in scai stage e shock, on an intra-aortic balloon pump (iabp), on multiple inotropes and vasopressors, and on a ventilator for respiratory support, prior to initiation of support.While the patient was in the intensive care unit (icu), there was bleeding around the impella site and bleeding at the femoral site where the iabp was removed.The following day after impella insertion, the patient expired on support.The impella functioned at p-9 at 3.5l/min as intended.Bleeding is a known risk due to the impella's anticoagulation and purge requirements.The impella is conservatively being reported for death; however, is unlikely to have contributed to the patient's death, which was most likely due to the clinical condition of a critically ill patient in acute myocardial infarction and cardiogenic shock, complicated by stage e shock.
|
| |
|
Event or Problem Description
|
|
Additional information was received: the peel-away sheath was removed, and a repositioning sheath was advanced without issue.Blood products were administered before and after impella cp insertion.
|
| |
|
Additional Manufacturer Narrative
|
|
B5 clinical narrative updated and h6 codes updated.Section d4 catalog number was corrected.
|
| |
|
Additional Manufacturer Narrative
|
|
Upon review, it was identified that the manufacturer fax (d3) was inadvertently omitted in error; the complete fax number has now been provided.Corrected information has been provided in d4 serial number.H6 investigation: type, findings, and conclusion codes and h6 component codes were updated accordingly based on the completed investigation.The cause of the access site adverse event was not determined due to insufficient clinical details.
|
| |
|
Search Alerts/Recalls
|